Michele Aventaggiato

Dr. Michele Aventaggiato

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MAMichele Aventaggiato
Michele Aventaggiato
EVEnza Vernucci
Enza Vernucci
FBFederica Barreca
Federica Barreca
MRMatteo A. Russo
Matteo A. Russo
MTMarco Tafani
Marco Tafani

28 January 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MIManuela Indelicato
Manuela Indelicato
BPBruna Pucci
Bruna Pucci
LSLuana Schito
Luana Schito
VRValentina Reali
Valentina Reali
MAMichele Aventaggiato
Michele Aventaggiato
MTMarco Tafani
Marco Tafani

28 January 2013 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Luigi SansoneLuigi Sansone
Luigi Sansone
VRValentina Reali
Valentina Reali
LPLaura Pellegrini
Laura Pellegrini
LVLidia Villanova
Lidia Villanova
MAMichele Aventaggiato
Michele Aventaggiato
BPBruna Pucci
Bruna Pucci

13 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BSBenjamin Suenkel
Benjamin Suenkel
SVSergio Valente
Sergio Valente
Clemens ZwergelClemens Zwergel
Clemens Zwergel
SWSandra Weiss
Sandra Weiss
EBElisabetta Di Bello
Elisabetta Di Bello
CSClemens Steegborn
Clemens Steegborn

9 May 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
EVEnza Vernucci
Enza Vernucci
CTCarlo Tomino
Carlo Tomino
FMFrancesca Molinari
Francesca Molinari
DLDolores Limongi
Dolores Limongi
MAMichele Aventaggiato
Michele Aventaggiato
Matteo A. RUSSOMatteo A. RUSSO
Matteo A. RUSSO
Mitochondria are the cellular center of energy production and of several important metabolic processes. Mitochondrion health is maintained with a substantial intervention of mitophagy, a process of macroautophagy that degrades selectively dysfunctional and irreversibly damaged organelles. Because of its crucial duty, alteration in mitophagy can cause functional and structural adjustment in the mitochondria, changes in energy production, loss of cellular adaptation, and cell death. In this review, we discuss the dual role that mitophagy plays in cancer and age-related pathologies, as a consequence of oxidative stress, evidencing the triggering stimuli and mechanisms and suggesting the molecular targets for its therapeutic control. Finally, a section has been dedicated to the interplay between mitophagy and therapies using nanoparticles that are the new frontier for a direct and less invasive strategy.

14 January 2019 in Cells
Verified
Journal Article
Open access
PDF file
SSSerena Saladini
Serena Saladini
MAMichele Aventaggiato
Michele Aventaggiato
FBFederica Barreca
Federica Barreca
EMEmanuela Morgante
Emanuela Morgante
Luigi SansoneLuigi Sansone
Luigi Sansone
MTMarco Tafani
Marco Tafani
Metformin has been shown to inhibit glutaminase (GLS) activity and ammonia accumulation thereby reducing the risk of hepatic encephalopathy in type 2 diabetic patients. Since tumour cells are addicted to glutamine and often show an overexpression of glutaminase, we hypothesize that the antitumoral mechanism of metformin could be ascribed to inhibition of GLS and reduction of ammonia and ammonia-induced autophagy. Our results show that, in different tumour cell lines, micromolar doses of metformin prevent cell growth by reducing glutamate, ammonia accumulation, autophagy markers such as MAP1LC3B-II and GABARAP as well as degradation of long-lived proteins. Reduced autophagy is then accompanied by increased BECN1/BCL2 binding and apoptotic cell death. Interestingly, GLS-silenced cells reproduce the effect of metformin treatment showing reduced MAP1LC3B-II and GABARAP as well as ammonia accumulation. Since metformin is used as adjuvant drug to increase the efficacy of cisplatin-based neoadjuvant chemotherapy, we co-treated tumour cells with micromolar doses of metformin in the presence of cisplatin observing a marked reduction of MAP1LC3B-II and an increase of caspase 3 cleavage. In conclusion, our work demonstrates that the anti-tumoral action of metformin is due to the inhibition of glutaminase and autophagy and could be used to improve the efficacy of chemotherapy.